Overview
Clinical Benefits
- Appetite suppression (distinct from GLP-1)
- Slows gastric emptying
- Synergistic with GLP-1 agonists
- Significant weight loss
Administration
Subcutaneous injection — abdomen, thigh, or upper arm
Drug class: amylin analog
Clinical Dosing
Typical dosage
0.16mg starting, titrate up to 2.4mg weekly
Starting dose
0.16mg
Cadence
Once weekly
Full titration schedule
| Phase | Dose |
|---|---|
| Weeks 1-4 | 0.16mg once weekly |
| Weeks 5-8 | 0.3mg once weekly |
| Weeks 9-12 | 0.6mg once weekly |
| Weeks 13-16 | 1.2mg once weekly |
| Weeks 17+ | 2.4mg once weekly (maintenance) |
Safety Profile
Side effects
- • Nausea
- • Vomiting
- • Diarrhea
- • Injection site reactions
Contraindications
- • Pregnancy
- • Pancreatitis history
- • Severe GI disease
Frequently asked questions
Cagrilintide is most commonly researched for: Appetite suppression (distinct from GLP-1), Slows gastric emptying, Synergistic with GLP-1 agonists, Significant weight loss.
Ready to build a protocol with Cagrilintide?
LIA, our clinical reasoning engine, will build a personalized protocol — dosing, cadence, cycling, and safety checks — tailored to your goals and intake.
You’ll be asked to sign in first. Free tier includes the chat preview.
Information on this page is for educational purposes only and is not medical advice. Peptides should only be used under the supervision of a qualified healthcare provider.